[Pharmacokinetic aspects of a combination of metoclopramide and paracetamol. Results of a human kinetic study and consequences for migraine patients].
An open trial was carried out in eight healthy male and female volunteers to examine the bioavailability as well as the main kinetic parameters of Migränerton (metoclopramide and paracetamol; CAS 364-64-5 and CAS 103-90-2, resp). in comparison with reliable literature data. The results reported here clearly show that the absorption of both active ingredients from the fixed combination is complete and that therapeutically relevant plasma concentrations are achieved within 30 min. Bioavailability as well as tmax, t1/2, and time-lag are comparable with data resulting from reliable and internationally acknowledged kinetic studies. The fixed combination was shown to be kinetically compatible with regard to all parameters determined for metoclopramide and paracetamol.
Becker
A
A
Forschungslaboratorien der Dolorgiet GmbH & Co. KG, St. Augustin/Bonn.
Berner
G
G
Leuschner
F
F
Vögtle-Junkert
U
U
D000082:Acetaminophen / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000328:Adult; D001682:Biological Availability; D004338:Drug Combinations; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D008787:Metoclopramide / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008881:Migraine Disorders / Q000188:drug therapy*
D004338:Drug Combinations; D000082:Acetaminophen; D008787:Metoclopramide
Pharmakokinetische Aspekte zur Kombination von Metoclopramid und Paracetamol. Ergebnisse einer Studie zur Humankinetik sowie Konsequenzen für den Migräne-Patienten.